Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
WST 
West Pharmaceutical Services Inc (WST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: WST (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 5.99% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.92B USD | Price to earnings Ratio 32.91 | 1Y Target Price 285.01 |
Price to earnings Ratio 32.91 | 1Y Target Price 285.01 | ||
Volume (30-day avg) 1116613 | Beta 1.09 | 52 Weeks Range 197.01 - 395.77 | Updated Date 04/1/2025 |
52 Weeks Range 197.01 - 395.77 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 0.38% | Basic EPS (TTM) 6.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 17.03% | Operating Margin (TTM) 22.94% |
Management Effectiveness
Return on Assets (TTM) 9.93% | Return on Equity (TTM) 17.71% |
Valuation
Trailing PE 32.91 | Forward PE 36.1 | Enterprise Value 15733667656 | Price to Sales(TTM) 5.5 |
Enterprise Value 15733667656 | Price to Sales(TTM) 5.5 | ||
Enterprise Value to Revenue 5.44 | Enterprise Value to EBITDA 21.15 | Shares Outstanding 72292704 | Shares Floating 71782456 |
Shares Outstanding 72292704 | Shares Floating 71782456 | ||
Percent Insiders 0.59 | Percent Institutions 97.11 |
Analyst Ratings
Rating 4.33 | Target Price 379.85 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
West Pharmaceutical Services Inc
Company Overview
History and Background
West Pharmaceutical Services, Inc. was founded in 1923. Initially focused on closures for pharmaceutical containers, it has evolved into a leading manufacturer of packaging components and drug delivery systems for injectable drugs.
Core Business Areas
- Proprietary Products: Includes stoppers, plungers, seals, and other components used in injectable drug delivery systems. Also includes Westar ready-to-sterilize components and NovaPure components.
- Contract-Manufactured Products: This segment includes drug delivery systems such as pen injectors, auto-injectors, and wearable injectors, manufactured for pharmaceutical and biotech companies.
Leadership and Structure
Eric M. Green is the current Chief Executive Officer. The company has a typical corporate structure with various departments including R&D, manufacturing, sales & marketing, and finance.
Top Products and Market Share
Key Offerings
- Elastomeric Closures: These are stoppers, plungers, and seals used to contain and deliver injectable drugs. West holds a significant portion of the market in this segment. Competitors include Datwyler, AptarGroup, and SCHOTT Pharmaceutical Packaging.
- Drug Delivery Devices: West designs and manufactures prefilled syringes, auto-injectors, and other drug delivery devices for pharmaceutical companies. West is becoming more competitive in this market due to its acquisition strategy. Competitors include SHL Medical, Ypsomed, and Gerresheimer.
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery systems market is growing, driven by the increasing demand for injectable drugs, biologics, and personalized medicine. Aging populations and chronic disease prevalence also contribute to market growth.
Positioning
West is a leading player in the injectable drug delivery market, known for its high-quality products, technical expertise, and strong customer relationships. They are strategically positioned to capitalize on the growth in injectable drugs.
Total Addressable Market (TAM)
The global pharmaceutical packaging market is projected to reach hundreds of billions of dollars. West is positioned to capture a significant share through its expertise in injectable drug delivery systems.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Extensive product portfolio
- Global manufacturing and distribution network
- Long-standing customer relationships
- Strong focus on innovation
Weaknesses
- Dependence on pharmaceutical industry trends
- Potential for product liability claims
- Exposure to raw material price fluctuations
- High capital expenditure requirements
- Reliance on few key customers
Opportunities
- Growing demand for injectable drugs and biologics
- Expansion into emerging markets
- Development of new drug delivery technologies
- Acquisitions of complementary businesses
- Increasing focus on patient safety and ease of use
Threats
- Competition from other pharmaceutical packaging and drug delivery companies
- Regulatory changes impacting drug packaging requirements
- Economic downturns affecting pharmaceutical spending
- Technological disruptions
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- DTC
- APT
- GCI
Competitive Landscape
West Pharmaceutical Services Inc. benefits from a broad product portfolio and strong customer relationships. However, competitors such as Datwyler and AptarGroup are also significant players with their own strengths and strategic focuses.
Major Acquisitions
HoloPlex
- Year: 2024
- Acquisition Price (USD millions): 130
- Strategic Rationale: Expanding West's biologics portfolio, HoloPlex enhances containment and delivery for complex molecules.
Growth Trajectory and Initiatives
Historical Growth: West has demonstrated consistent revenue growth driven by organic growth and acquisitions.
Future Projections: Analysts project continued revenue growth in the mid-single digits, driven by demand for injectable drugs and drug delivery devices.
Recent Initiatives: Recent initiatives include investments in capacity expansion, new product development, and acquisitions to strengthen its market position.
Summary
West Pharmaceutical Services is a strong player in the injectable drug delivery market, benefiting from a diversified portfolio and long-standing customer relationships. Continued growth will depend on innovation and strategic acquisitions. They need to watch out for regulatory changes and growing completion.
Similar Companies
- DTC
- APT
- GCI
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Investor Presentations, Analyst Reports, News Articles
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About West Pharmaceutical Services Inc
Exchange NYSE | Headquaters Exton, PA, United States | ||
IPO Launch date 1978-01-13 | Non-Independent Chair of the Board, President & CEO Mr. Eric M. Green | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.westpharma.com |
Full time employees 10600 | Website https://www.westpharma.com | ||
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.